Is nervus femoralis radiofrequency ablation an effective treatment for recalcitrant greater trochanteric pain syndrome? Results of a cross-sectional study - Summary - MDSpire
Advertisement
Is nervus femoralis radiofrequency ablation an effective treatment for recalcitrant greater trochanteric pain syndrome? Results of a cross-sectional study
To describe long-term treatment outcomes of nervus femoralis radiofrequency ablation (NF-RFA) for recalcitrant greater trochanteric pain syndrome (GTPS), focusing on the primary outcome of ≥50% NPRS score reduction.
Key Findings:
55.6% of patients reported ≥50% NPRS reduction from baseline (95% CI: 37.3-72.4).
51.9% reported PGIC scores indicating 'much improved' or 'very much improved' (95% CI: 34.0-69.3).
Average follow-up time was 13.1 months.
Approximately 25% reported ongoing pain or return of symptoms post-procedure.
Interpretation:
Over half of the patients experienced significant pain relief from NF-RFA, indicating its potential as an effective treatment for refractory GTPS, which may influence future treatment protocols.
Limitations:
Small sample size of 25 patients limits generalizability.
Retrospective nature of the study may introduce bias.
Follow-up duration varied among patients, potentially affecting outcome consistency.
Conclusion:
NF-RFA appears to be a promising intervention for patients with persistent GTPS, with a majority reporting substantial pain relief and improvement in quality of life, warranting further research to validate these findings.
by Kristen Saad, Chase Young, Amanda N Cooper, Blake Dickenson, Richard Kendall, Allison Glinka Przybysz, Taylor Burnham, Zachary L McCormick, Aaron Conger
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
